Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
Business12 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…